Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 2/2018

01-04-2018 | Correspondence

Platelet Count, D-Dimer, Component Therapy and Dengue Hemorrhagic Fever

Authors: Beuy Joob, Viroj Wiwanitkit

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2018

Login to get access

Excerpt

Dear Editor, Sridhar et al. reported an interesting finding on “Correlation of the Platelet Count with D-Dimer Levels as an Indicator for Component Therapy in Children with Dengue Hemorrhagic Fever (DHF)” [1]. Sridhar et al. concluded that “DHF children with thrombocytopenia and features of shock, aggressive component therapy may prevent subsequent bleeding and may be justified [1].” In fact, the standard management of DHF with or without shock is fluid replacement therapy with closed monitoring [2]. The role of using component therapy is controversial. In the present report, there are many considerations. First, using seropositive as a selection criterion for inclusion might not successfully exclude many similar tropical diseases that can have cross reactive with dengue. Second, there is no evaluation on the effectiveness and clinical utility of using component therapy. Third, in any DHF cases with or without shock, D-dimer can be increased [3]. There is also no proof that having transfusion therapy for DHF with shock results in better clinical outcome than standard fluid replacement therapy [2]. In case that transfusion therapy is selected, the reason is usually severe bleeding presentation but not shock [4]. …
Literature
1.
go back to reference Sridhar A, Sunil Kumar BM, Rau A, Rau ATK (2017) A correlation of the platelet count with D-dimer levels as an indicator for component therapy in children with dengue hemorrhagic fever. Indian J Hematol Blood Transfus 33(2):222–227PubMedCrossRef Sridhar A, Sunil Kumar BM, Rau A, Rau ATK (2017) A correlation of the platelet count with D-dimer levels as an indicator for component therapy in children with dengue hemorrhagic fever. Indian J Hematol Blood Transfus 33(2):222–227PubMedCrossRef
2.
go back to reference Wiwanitkit V (2010) Dengue fever: diagnosis and treatment. Expert Rev Anti Infect Ther 8(7):841–845PubMedCrossRef Wiwanitkit V (2010) Dengue fever: diagnosis and treatment. Expert Rev Anti Infect Ther 8(7):841–845PubMedCrossRef
3.
go back to reference Orsi FA, Angerami RN, Mazetto BM, Quaino SK, Santiago-Bassora F, Castro V, de Paula EV, Annichino-Bizzacchi JM (2013) Reduced thrombin formation and excessive fibrinolysis are associated with bleeding complications in patients with dengue fever: a case-control study comparing dengue fever patients with and without bleeding manifestations. BMC Infect Dis 28(13):350CrossRef Orsi FA, Angerami RN, Mazetto BM, Quaino SK, Santiago-Bassora F, Castro V, de Paula EV, Annichino-Bizzacchi JM (2013) Reduced thrombin formation and excessive fibrinolysis are associated with bleeding complications in patients with dengue fever: a case-control study comparing dengue fever patients with and without bleeding manifestations. BMC Infect Dis 28(13):350CrossRef
4.
go back to reference Moulton SL, Mulligan J, Srikiatkhachorn A, Kalayanarooj S, Grudic GZ, Green S, Gibbons RV, Muniz GW, Hinojosa-Laborde C, Rothman AL, Thomas SJ, Convertino VA (2016) State-of-the-art monitoring in treatment of dengue shock syndrome: a case series. J Med Case Rep 10(1):233PubMedPubMedCentralCrossRef Moulton SL, Mulligan J, Srikiatkhachorn A, Kalayanarooj S, Grudic GZ, Green S, Gibbons RV, Muniz GW, Hinojosa-Laborde C, Rothman AL, Thomas SJ, Convertino VA (2016) State-of-the-art monitoring in treatment of dengue shock syndrome: a case series. J Med Case Rep 10(1):233PubMedPubMedCentralCrossRef
Metadata
Title
Platelet Count, D-Dimer, Component Therapy and Dengue Hemorrhagic Fever
Authors
Beuy Joob
Viroj Wiwanitkit
Publication date
01-04-2018
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2018
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-017-0861-5

Other articles of this Issue 2/2018

Indian Journal of Hematology and Blood Transfusion 2/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine